Marc Tebruegge

Marc Tebruegge

Auto-generated profile, based on publicly available information

Marc Tebruegge

Department of Child and Adolescent Medicine, Klinik Ottakring, Vienna Healthcare Group & Austrian Reference Centre for Childhood Tuberculosis, Vienna, Austria

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
FGFlorian Götzinger
Florian Götzinger
BSBegoña Santiago-García
Begoña Santiago-García
ANAntoni Noguera-Julián
Antoni Noguera-Julián
MLMiguel Lanaspa
Miguel Lanaspa
LLLaura Lancella
Laura Lancella
ARAndrew Riordan
Andrew Riordan

1 July 2015 in Journal of Infection
Verified
Journal Article
Closed access
PZPetra Zimmermann
Petra Zimmermann
MTMarc Tebruegge
Marc Tebruegge
NCNigel Curtis
Nigel Curtis
NRNicole Ritz
Nicole Ritz

26 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMarc Tebruegge
Marc Tebruegge
APAnastasia Pantazidou
Anastasia Pantazidou
DMDuncan MacGregor
Duncan MacGregor
GGGena Gonis
Gena Gonis
DLDavid Leslie
David Leslie
NCNigel Curtis
Nigel Curtis
There are limited data on the epidemiology, diagnosis and optimal management of nontuberculous mycobacterial (NTM) disease in children. Retrospective cohort study of NTM cases over a 10-year-period at a tertiary referral hospital in Australia. A total of 140 children with NTM disease, including 107 with lymphadenitis and 25 with skin and soft tissue infections (SSTIs), were identified. The estimated incidence of NTM disease was 0.6–1.6 cases / 100,000 children / year; no increasing trend was observed over the study period. Temporal analyses revealed a seasonal incidence cycle around 12 months, with peaks in late winter/spring and troughs in autumn. Mycobacterium-avium-complex accounted for most cases (77.8%), followed by Mycobacterium ulcerans (14.4%) and Mycobacterium marinum (3.3%). Polymerase chain reaction testing had higher sensitivity than culture and microscopy for acid-fast bacilli (92.0%, 67.2% and 35.7%, respectively). The majority of lymphadenitis cases underwent surgical excision (97.2%); multiple recurrences in this group were less common in cases treated with clarithromycin and rifampicin compared with clarithromycin alone or no anti-mycobacterial drugs (0% versus 7.1%; OR:0.73). SSTI recurrences were also less common in cases treated with two anti-mycobacterial drugs compared with one or none (10.5% versus 33.3%; OR:0.23). There was seasonal variation in the incidence of NTM disease, analogous to recently published observations in tuberculosis, which have been linked to seasonal variation in vitamin D. Our finding that anti-mycobacterial combination therapy was associated with a reduced risk of recurrences in patients with NTM lymphadenitis or SSTI requires further confirmation in prospective trials.

1 July 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
MTMarc Tebruegge
Marc Tebruegge
HGHans de Graaf
Hans de Graaf
PSPriya Sukhtankar
Priya Sukhtankar
PEPaul Elkington
Paul Elkington
BMBen Marshall
Ben Marshall
SFSaul N. Faust
Saul N. Faust
Results from 3,263 QuantiFERON-TB Gold in-tube (QFT-GIT) assays were analyzed to determine the impact of age on test performance. The proportion of indeterminate results was significantly higher in pediatric and elderly (9.1% and 7.4%, respectively) than in adult (2.6%; chi-square test, P < 0.0001) patients. A detailed analysis of indeterminate QFT-GIT assay results is presented.

17 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
DGDiana J. Garay-Baquero
Diana J. Garay-Baquero
CWCory White
Cory White
NWNaomi F. Walker
Naomi F. Walker
MTMarc Tebruegge
Marc Tebruegge
HSHannah F. Schiff
Hannah F. Schiff
PEPaul Elkington
Paul Elkington
BACKGROUND: Tuberculosis (TB) kills more people than any other infection, and new diagnostic tests to identify active cases are required. We aimed to discover and verify novel markers for TB in nondepleted plasma. METHODS: We applied an optimized quantitative proteomics discovery methodology based on multidimensional and orthogonal liquid chromatographic separation combined with high-resolution mass spectrometry to study nondepleted plasma of 11 patients with active TB compared with 10 healthy controls. Prioritized candidates were verified in independent UK ( n = 118) and South African cohorts ( n = 203). RESULTS: We generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 11 orders-of-magnitude concentration range with diverse biochemical and molecular properties. We analyzed the predominantly low–molecular weight subproteome, identifying 46 proteins with significantly increased and 90 with decreased abundance (peptide FDR ≤ 1%, q ≤ 0.05). Verification was performed for novel candidate biomarkers (CFHR5, ILF2) in 2 independent cohorts. Receiver operating characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP, and SAA1) exhibited discriminatory power in distinguishing TB from other respiratory diseases (AUC = 0.81). CONCLUSION: We report the most comprehensive TB plasma proteome to date, identifying novel markers with verification in 2 independent cohorts, leading to a 5-protein biosignature with potential to improve TB diagnosis. With further development, these biomarkers have potential as a diagnostic triage test. FUNDING: Colciencias, Medical Research Council, Innovate UK, NIHR, Academy of Medical Sciences, Program for Advanced Research Capacities for AIDS, Wellcome Centre for Infectious Diseases Research.

1 January 2019 in Tuberculosis
Verified
Journal Article
Closed access
VCVanessa Clifford
Vanessa Clifford
MTMarc Tebruegge
Marc Tebruegge
CZChristel Zufferey
Christel Zufferey
SGSusie Germano
Susie Germano
BFBen Forbes
Ben Forbes
NCNigel Curtis
Nigel Curtis